Zafgen Inc (NASDAQ:ZFGN) has been assigned an average rating of “Hold” from the nine research firms that are covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $2.76.
Several analysts have issued reports on ZFGN shares. Roth Capital downgraded shares of Zafgen from a “buy” rating to a “neutral” rating in a research note on Friday, September 6th. Wedbush reissued a “hold” rating and set a $0.78 target price on shares of Zafgen in a research note on Thursday, November 14th. JMP Securities downgraded shares of Zafgen from an “outperform” rating to a “market perform” rating in a research note on Thursday, September 5th. Finally, Zacks Investment Research raised shares of Zafgen from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research note on Thursday, November 21st.
Shares of NASDAQ:ZFGN traded down $0.03 on Tuesday, reaching $0.82. 286,114 shares of the company traded hands, compared to its average volume of 318,438. Zafgen has a fifty-two week low of $0.63 and a fifty-two week high of $5.76. The company’s 50 day moving average is $0.78 and its 200-day moving average is $0.98. The stock has a market capitalization of $31.77 million, a PE ratio of -0.43 and a beta of -0.56. The company has a debt-to-equity ratio of 0.28, a current ratio of 5.11 and a quick ratio of 5.11.
Several hedge funds and other institutional investors have recently bought and sold shares of ZFGN. Citadel Advisors LLC increased its stake in shares of Zafgen by 2.2% in the second quarter. Citadel Advisors LLC now owns 971,818 shares of the biopharmaceutical company’s stock worth $1,156,000 after purchasing an additional 20,953 shares in the last quarter. Morgan Stanley lifted its position in Zafgen by 150.8% during the second quarter. Morgan Stanley now owns 184,606 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 110,989 shares during the last quarter. AWM Investment Company Inc. raised its stake in shares of Zafgen by 32.4% during the second quarter. AWM Investment Company Inc. now owns 1,857,171 shares of the biopharmaceutical company’s stock worth $2,210,000 after acquiring an additional 454,874 shares in the last quarter. Wedbush Securities Inc. raised its stake in shares of Zafgen by 122.2% during the third quarter. Wedbush Securities Inc. now owns 170,000 shares of the biopharmaceutical company’s stock worth $126,000 after acquiring an additional 93,500 shares in the last quarter. Finally, Northeast Financial Consultants Inc purchased a new position in shares of Zafgen during the second quarter worth approximately $28,000. 61.49% of the stock is currently owned by institutional investors and hedge funds.
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Featured Article: Pattern Day Trader – What is the PDT Rule?
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.